203 related articles for article (PubMed ID: 26178079)
21. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
22. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
23. Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor.
Choi S; Lim MH; Kim KM; Jeon BH; Song WO; Kim TW
Toxicol Appl Pharmacol; 2011 Dec; 257(2):165-73. PubMed ID: 21933677
[TBL] [Abstract][Full Text] [Related]
24. Photo-activated pheophorbide-a, an active component of Scutellaria barbata, enhances apoptosis via the suppression of ERK-mediated autophagy in the estrogen receptor-negative human breast adenocarcinoma cells MDA-MB-231.
Bui-Xuan NH; Tang PM; Wong CK; Fung KP
J Ethnopharmacol; 2010 Aug; 131(1):95-103. PubMed ID: 20558270
[TBL] [Abstract][Full Text] [Related]
25. Transient receptor potential melastatin 7 channels are involved in ginsenoside Rg3-induced apoptosis in gastric cancer cells.
Kim BJ; Nah SY; Jeon JH; So I; Kim SJ
Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):233-9. PubMed ID: 21443732
[TBL] [Abstract][Full Text] [Related]
26. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
27. TRPM2 mediates distruption of autophagy machinery and correlates with the grade level in prostate cancer.
Tektemur A; Ozaydin S; Etem Onalan E; Kaya N; Kuloglu T; Ozercan İH; Tekin S; Elyas HM
J Cancer Res Clin Oncol; 2019 May; 145(5):1297-1311. PubMed ID: 30888515
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
29. Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
Shemesh CS; Hardy CW; Yu DS; Fernandez B; Zhang H
Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):193-203. PubMed ID: 24657627
[TBL] [Abstract][Full Text] [Related]
30. Antagonism of the transient receptor potential melastatin‑2 channel leads to targeted antitumor effects in primary human malignant melanoma cells.
McKamey SG; Jira LR; Tweed CM; Blake SD; Powell DP; Daghistani AT; Koh DW
Int J Oncol; 2022 Apr; 60(4):. PubMed ID: 35234266
[TBL] [Abstract][Full Text] [Related]
31. Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.
Tyutyunyk-Massey L; Sun Y; Dao N; Ngo H; Dammalapati M; Vaidyanathan A; Singh M; Haqqani S; Haueis J; Finnegan R; Deng X; Kirberger SE; Bos PD; Bandyopadhyay D; Pomerantz WCK; Pommier Y; Gewirtz DA; Landry JW
Mol Cancer Res; 2021 Aug; 19(8):1338-1349. PubMed ID: 33811160
[TBL] [Abstract][Full Text] [Related]
32. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
Hall SR; Toulany J; Bennett LG; Martinez-Farina CF; Robertson AW; Jakeman DL; Goralski KB
J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004
[TBL] [Abstract][Full Text] [Related]
33. Facilitation of H2O2-induced A172 human glioblastoma cell death by insertion of oxidative stress-sensitive TRPM2 channels.
Ishii M; Oyama A; Hagiwara T; Miyazaki A; Mori Y; Kiuchi Y; Shimizu S
Anticancer Res; 2007; 27(6B):3987-92. PubMed ID: 18225560
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of autophagy stimulate molecular iodine-induced apoptosis in hormone independent breast tumors.
Singh P; Godbole M; Rao G; Annarao S; Mitra K; Roy R; Ingle A; Agarwal G; Tiwari S
Biochem Biophys Res Commun; 2011 Nov; 415(1):181-6. PubMed ID: 22027149
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.
Ravi M; Tentu S; Baskar G; Rohan Prasad S; Raghavan S; Jayaprakash P; Jeyakanthan J; Rayala SK; Venkatraman G
BMC Cancer; 2015 Oct; 15():768. PubMed ID: 26499490
[TBL] [Abstract][Full Text] [Related]
36. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.
Goh W; Sleptsova-Freidrich I; Petrovic N
J Pharm Pharm Sci; 2014; 17(3):439-46. PubMed ID: 25224353
[TBL] [Abstract][Full Text] [Related]
37. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase.
Fonfria E; Marshall IC; Benham CD; Boyfield I; Brown JD; Hill K; Hughes JP; Skaper SD; McNulty S
Br J Pharmacol; 2004 Sep; 143(1):186-92. PubMed ID: 15302683
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity.
El-Ashmawy NE; Al-Ashmawy GM; Amr EA; Khedr EG
Life Sci; 2020 Oct; 259():118212. PubMed ID: 32768581
[TBL] [Abstract][Full Text] [Related]
39. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
